Molecular‐targeting therapies against quantitative abnormalities in gene expression with malignant tumors
Authors:
Open Access
- 12 April 2017
- journal article
- review article
- Published by Wiley in Cancer Science
- Vol. 108 (4) , 570-573
Abstract
Genetic mutations in exons of oncogenes and tumor‐suppressor genes causing qualitative abnormalities result in activation of the oncogenes and inactivation of the tumor‐suppressor genes, thereby causing cancer. In contrast, we have previously demonstrated that decreases in the RB promoter activity by genetic or epigenetic abnormalities can also cause carcinogenesis. In addition, activation and inactivation of a variety of oncogenes and tumor‐suppressor genes finally cause quantitative abnormalities in gene expression. Interestingly, we discovered effective molecular‐targeting agents, such as a novel MEK inhibitor, trametinib, by screening for agents upregulating the expression of cyclin‐dependent kinase inhibitors. In the present review, we focused on the quantitative abnormalities in gene expression with carcinogenesis, and discuss the importance of normalizing the quantitative abnormalities in gene expression with several molecular‐targeting agents.Keywords
This publication has 42 references indexed in Scilit:
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 MutationsNew England Journal of Medicine, 2012
- Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivoInternational Journal of Oncology, 2011
- Trichostatin A activates p18INK4cgene: differential activation and cooperation with p19INK4dgeneFEBS Letters, 2004
- The discovery of receptor tyrosine kinases: targets for cancer therapyNature Reviews Cancer, 2004
- The history of cancer epigeneticsNature Reviews Cancer, 2004
- p53-independent induction of Gadd45 by histone deacetylase inhibitor: coordinate regulation by transcription factors Oct-1 and NF-YOncogene, 2003
- p15INK4b in HDAC inhibitor‐induced growth arrestFEBS Letters, 2003
- Suppression of ARG kinase activity by STI571 induces cell cycle arrest through up-regulation of CDK inhibitor p18/INK4cOncogene, 2003
- Molecular mechanisms underlying ErbB2/HER2 action in breast cancerOncogene, 2000
- Cancer Cell CyclesScience, 1996